STOCK TITAN
  1. Home
  2. Sec-filings
  3. NRIX
  4. [Form 4] Nurix Therapeutics, Inc. Insider Trading Activity

Nurix Therapeutics (NASDAQ: NRIX) CSO sells 4,111 shares under 10b5-1 plan

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen reported selling a total of 4,111 shares of common stock on 2026-08-04 in two transactions at weighted average prices of $23.8684 and $24.6415. The sales were effected pursuant to a previously adopted Rule 10b5-1 trading plan.

Positive

  • None.

Negative

  • None.
Insider Hansen Gwenn
Role Chief Scientific Officer
Sold 4,111 shs ($100K)
Type Security Shares Price Value
Sale Common Stock F1, F2 1,500 $23.8684 $36K
Sale Common Stock F1, F3 2,611 $24.6415 $64K
Holdings After Transaction: Common Stock — 117,227 shares (Direct)
Footnotes (3)
  1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
  2. F2. Represents the weighted average sale price. The lowest price at which shares were sold was $23.42 and the highest price at which shares were sold was $24.38. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
  3. F3. Represents the weighted average sale price. The lowest price at which shares were sold was $24.43 and the highest price at which shares were sold was $24.83. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
Shares sold (first transaction) 1,500 shares Common stock sale on 2026-08-04 at weighted average price $23.8684
Shares sold (second transaction) 2,611 shares Common stock sale on 2026-08-04 at weighted average price $24.6415
Total shares sold 4,111 shares Aggregate of reported common stock sales on 2026-08-04
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"Represents the weighted average sale price."
Sale in open market or private transaction regulatory
"transaction code description: Sale in open market or private transaction"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transaction did Nurix Therapeutics (NRIX) report in this Form 4?
Nurix Therapeutics reported that Chief Scientific Officer Gwenn Hansen sold 4,111 shares of common stock on 2026-08-04. The sales occurred in two separate transactions at weighted average prices of $23.8684 and $24.6415 under a Rule 10b5-1 trading plan.

How many NRIX shares did Gwenn Hansen sell and at what prices?
Gwenn Hansen sold 4,111 NRIX shares in total on 2026-08-04. One sale covered 1,500 shares at a weighted average of $23.8684, and another covered 2,611 shares at a weighted average of $24.6415, each within disclosed price ranges.

Were the NRIX insider sales by Gwenn Hansen under a Rule 10b5-1 plan?
Yes. The filing states the transactions were effected pursuant to a previously adopted Rule 10b5-1 trading plan. Such plans pre-schedule trades, meaning the timing of these sales was determined in advance rather than decided on the trade date.

What price ranges applied to the NRIX shares sold by Gwenn Hansen?
For the 1,500-share sale, prices ranged from $23.42 to $24.38. For the 2,611-share sale, prices ranged from $24.43 to $24.83. The reported per-share figures are weighted average sale prices across these ranges.

What is the transaction code used for Gwenn Hansen’s NRIX trades?
Both transactions use code S, described as a “Sale in open market or private transaction.” This indicates dispositions of common stock rather than purchases or option exercises, and both are reported as direct ownership transactions.

Does the Form 4 disclose Gwenn Hansen’s NRIX holdings after these sales?
No specific post-transaction share balance is provided for these trades. The Form 4 reports the number of shares sold and their weighted average prices, but the fields for total shares following the transactions are left blank.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hansen Gwenn
(Last)(First)(Middle)
C/O NURIX THERAPEUTICS, INC.
1600 SIERRA POINT PKWY
(Street)
BRISBANE CALIFORNIA 94005
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Scientific Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/04/2026S(1)1,500D$23.8684(2)119,838D
Common Stock08/04/2026S(1)2,611D$24.6415(3)117,227D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
2. Represents the weighted average sale price. The lowest price at which shares were sold was $23.42 and the highest price at which shares were sold was $24.38. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
3. Represents the weighted average sale price. The lowest price at which shares were sold was $24.43 and the highest price at which shares were sold was $24.83. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
Remarks:
/s/ Daniel Burbach, as Attorney-in-Fact for Gwenn Hansen08/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR